Y Western blotpeting interests The authors declare that they have no competing interests. Authors’ contributions PK, LZ, MHL, SMD, and JML are responsible for the study design. PK, LZ and MHL, performed the experiments and collected the data. PK, LZ, MHL, FB, GL, MS, GW, SS, SMD, and JML participated inside the information analysis and interpretation. PK, MHL, TCW, KK, SMD, and JML drafted the manuscript. All authors study and authorized the final manuscript. Acknowledgements This function was supported in part by funding in the Pulmonary and Critical Care Medicine Training System (NIH/NHLBI 5T32HL072752), NCI (L30 CA142223-01 and 1 K23 CA131577-01A1), Thoracic Surgery Foundation for Research and Education (TSFRE) Grant, Jonsson Cancer Center Foundation, Stop Cancer Investigation Award, the Ronald Binder Memorial Fund for Lung Cancer Analysis, NIH/NCATS (UL1TR000124), and Health-related Investigation Funds from the Division of Veterans Affairs (Merit Evaluation 5I01BX000359 and 1I01CX000345-01).Kachroo et al. Journal of Experimental Clinical Cancer Study 2013, 32:97 http://www.jeccr/content/32/1/Page 13 ofAuthor information 1 Lung Cancer Study Plan, Jonsson Extensive Cancer Center, Los Angeles, CA, USA. 2Division of Pulmonary and Critical Care Medicine, Los Angeles, CA, USA. 3Division of Thoracic Surgery in the David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 4Molecular Gene Medicine Laboratory, Veterans Affair Greater Los Angeles Healthcare Technique, Los Angeles, CA, USA. 5Division of Thoracic Surgery, Ronald Reagan UCLA Health-related Center, Room 64-128 CHS, 10833 Le Conte Ave, Box 957313, Los Angeles, CA 90095-7313, USA. Received: 14 August 2013 Accepted: 22 November 2013 Published: 25 November 2013 References 1. Villarino AV, Huang E, Hunter CA: Understanding the pro- and antiinflammatory properties of IL-27. J Immunol 2004, 173(2):71520. 2. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM: IL-27 mediates comprehensive regression of orthotopic major and metastatic murine neuroblastoma tumors: part for CD8+ T cells. J Immunol 2004, 173(12):7170182. three. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I: Interleukin-27 acts as multifunctional antitumor agent in numerous myeloma. Clin Cancer Res 2010, 16(16):4188197. 4. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, Tagawa M: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.SiRNA Control Int J Cancer 2005, 115(3):43742.Anti-Mouse Ly-6G/Ly-6C Antibody five.PMID:23892746 Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, et al: Antiangiogenic and antitumor activities of IL-27. J Immunol 2006, 176(12):7317324. six. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T: Potent antitumor activity of interleukin-27. Cancer Res 2004, 64(three):1152156. 7. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C: Interleukin-23 and interleukin-27 exert very unique antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006, 66(12):6395404. 8. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J: Antiproliferative activity of IL-27 on melanoma. J Immunol 2008, 180(10):6527535. 9. Hurteau JA, Blessing JA, DeCesare SL, Creasman WT: Evaluation of recomb.
